Gabriel M. Knight, Jeffrey Clark, Justin R. Boike, Haripriya Maddur, Daniel R. Ganger, Abhinav Talwar, Ahsun Riaz, Kush Desai, Samdeep Mouli, Elias Hohlastos, Juan‐Carlos Garcia Pagan, Ahmed Gabr, Brady Stein, Robert Lewandowski, Bartley Thornburg, Riad Salem – 20 May 2021
Marina Serper, Sunny Y. Tao, Dorothea S. Kent, Patrik Garren, Alexander E. Burdzy, Jennifer C. Lai, Amir Gougol, Pamela M. Bloomer, K. Rajender Reddy, Michael A. Dunn, Andres Duarte‐Rojo – 20 May 2021 – Objective inpatient frailty assessments in decompensated cirrhosis are understudied. We examined the feasibility of inpatient frailty measurements and associations with nonhome discharge, readmission, and all‐cause mortality among patients admitted for cirrhosis complications. We conducted a prospective study at 3 liver transplantation (LT) centers.
Chathur Acharya, Jasmohan S. Bajaj – 20 May 2021 – Cirrhosis is a debilitating chronic disease with high morbidity and mortality, with the only real cure being liver transplantation (LT). Currently, we allocate organs for transplantation based on the Model for End‐Stage Liver Disease–Sodium (MELD‐Na) score that does not account for hepatic encephalopathy (HE). HE affects patients, families, and the health care system because of high rates of recurrence and major readmission burden. Moreover, HE casts a long shadow even after LT.
Kathleen Yan, Lisa Forman – 20 May 2021 – The effect of cannabinoids on liver transplant outcomes is an area of active research. We aimed to investigate marijuana (MJ) and cannabidiol (CBD) use among liver transplant recipients at the University of Colorado Hospital (UCH), specifically prevalence, habits, and predictors of use. Liver transplant recipients followed at UCH with valid email addresses were sent an informed consent postcard and survey invitation. This exploratory survey was conducted using REDCap. IBM SPSS Statistics software was used for statistical analysis.
Join the Nonalcoholic Fatty Liver Disease Special Interest Group in discussing the current challenges in histological assessment in NASH clinical trials. Presenters will also discuss how to implement hard outcomes in NASH clinical trials and the use non-invasive biomarkers as primary endpoints for drug approval.Naim Alkhouri Naim Alkhouri, MD is the VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Prior to joining ALH, Dr.
Madelon L. Geurtsen, Rama J. Wahab, Janine F. Felix, Romy Gaillard, Vincent W.V. Jaddoe – 17 May 2021
Lukas Hartl, Georg Semmler, Benedikt Silvester Hofer, Nawa Schirwani, Mathias Jachs, Benedikt Simbrunner, David Josef Maria Bauer, Teresa Binter, Katharina Pomej, Matthias Pinter, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Bernhard Scheiner – 17 May 2021 – The coronavirus disease 2019 (COVID‐19) pandemic necessitated down‐scaling of in‐hospital care to prohibit the spread of severe acute respiratory syndrome–coronavirus‐2.
Gautam Mehta, Rajiv Jalan – 17 May 2021
Magdalena Meszaros, Régine Truchi, Denis Ouzan, Albert Tran, Marc Bourlière, Georges‐Philippe Pageaux – 17 May 2021
Mercedes Martinez, Emily R. Perito, Pamela Valentino, Cara L Mack, Madeleine Aumar, Annemarie Broderick, Laura G. Draijer, Eleonora D.T. Fagundes, Katryn N. Furuya, Nitika Gupta, Simon Horslen, Maureen M. Jonas, Binita M. Kamath, Nanda Kerkar, Kyung Mo Kim, Kaija‐Leena Kolho, Bart G.P. Koot, Trevor J. Laborda, Christine K. Lee, Kathleen M. Loomes, Tamir Miloh, Douglas Mogul, Saeed Mohammed, Nadia Ovchinsky, Girish Rao, Amanda Ricciuto, Alexandre Rodrigues Ferreira, Kathleen B. Schwarz, Vratislav Smolka, Atsushi Tanaka, Mary E.M. Tessier, Venna L. Venkat, Bernadette E.